循环性肿瘤细胞市场规模、份额、成长分析、按产品、按检体、按技术、按应用、按最终用户 - 行业预测，2024-2031

2022年，全球循环性肿瘤细胞市场规模为103.2亿美元，从2023年的113.8亿美元成长到2031年的249.4亿美元，预计在预测期内（2024-2031年）将成长。 %。

大多数恶性诊断的突破性进展正在为全球循环性肿瘤细胞（CTC）市场创造充满希望的市场动力。大多数恶性的盛行率不断上升，增加了对 CTC 评估等非侵入性诊断工具的需求。两个主要动机是越来越关注定製药物治疗以及大多数病例早期发现癌症的需要。然而，技术复杂性和标准化愿望等障碍阻碍了大规模接受。基于 PCR 和 ELISA 的方法是最常见的产品类型。北美拥有完善的医疗基础设施并拥有较大的市场占有率。为满足不断变化的医疗需求而进行的持续研究、合作伙伴关係和产品改进是该市场的特征。

目录

介绍

• 这项研究的目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场危机与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价值链分析
• 价格分析
• Start-Ups分析
• 监管环境
• 专利分析
• 管道分析
• 成功的关键因素
• 市场吸引力指数
• 竞争程度
• 主要投资机会
• 生态系绘图

依技术分类：循环性肿瘤细胞市场

• 市场概况
• CTC检测
  • 免疫捕获
  • 按尺寸分离
  • 基于密度的分离
  • 组合法
• CTC检测方法
  • 非典
  • 显微镜检查
  • 其他的
• CTC分析

依应用分类：循环性肿瘤细胞市场

• 市场概况
• 临床液态生物检体
  • 风险评估
  • 筛检和监测
• 研究
  • 癌症干细胞
  • 药物治疗的发展

按最终用户：循环性肿瘤细胞市场

• 市场概况
• 医院/诊所，
• 研究/学术机构
• 诊断中心

副产品：循环性肿瘤细胞市场

• 市场概况
• 套件和试剂
• 采血管
• 设备或系统

依检体：循环性肿瘤细胞市场

• 市场概况
• 血
• 骨髓
• 其他检体

按地区划分：循环性肿瘤细胞市场规模

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Janssen Diagnostics（Johnson & Johnson）
• Sysmex America, Inc.
• Qiagen
• Roche Diagnostics
• BD（Becton, Dickinson and Company）
• Macrogenics, Inc.
• Personalis, Inc.
• ANGLE PLC
• ApoCell, Inc.
• RareCyte, Inc.
• Exosomedx
• Grail, Inc.
• Invivoscribe Technologies, LLC
• Epic Sciences, Inc.
• Circulating Biomarkers LLC
• ClariCell, Inc.
• Thrive Earlier Detection
• Ellumen
• Hera BioLabs
• CellMax Life Technologies

Global Circulating Tumor Cell Market size was valued at USD 10.32 billion in 2022 and is poised to grow from USD 11.38 billion in 2023 to USD 24.94 billion by 2031, growing at a CAGR of 10.3% during the forecast period (2024-2031).

The breakthroughs in the diagnosis of most malignancies have created promising market dynamics for the worldwide Circulating Tumor Cell (CTC) market. The increasing prevalence of most malignancies drives up demand for non-invasive diagnostic tools such as CTC assessment. Two major motivators are the increasing focus on customized medications and the necessity of early cancer detection for the majority of cases. Massive acceptance is prevented, nevertheless, by obstacles including technological complexity and the desire for standardization. PCR and ELISA-based approaches are the most common types of products. North America's well-established healthcare infrastructure contributes to its large market share. Continuous research, partnerships, and product improvements to meet changing medical needs are what define the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Circulating Tumor Cell Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Circulating Tumor Cell Market Segmental Analysis

The global circulating tumor cell market is segmented into product, specimen, technology, application, end user, and region. Based on product, the market is segmented into Kits & Reagents, Blood Collection Tubes, Devices or Systems. Based on specimen, the market is segmented into Blood, Bone Marrow, other body fluid. Based on technology, the market is segmented into CTC Detection (Immunocapture, Size-based separation, Density Based Separation, Combined Methods), CTC Detection method (SERS, Microscopy, Others), CTC Analysis. Based on application, the market is segmented into Clinical Liquid Biopsy (Risk Assessment, Screening and Monitoring), Research (Cancer Stem Cell, Drug Therapy Development). Based on end user, the market is segmented into Hospitals & Clinics, Research & Academic Institutes, Diagnostic Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Drivers of the Global Circulating Tumor Cell Market

The need for better diagnostic tools has increased due to the rising incidence of cancer worldwide. CTC evaluation has emerged as a valuable and non-invasive technique for cancer tracking and diagnosis. The desire for early cancer diagnosis and the focus on personalized medicine are driving the adoption of CTC technologies in a similar way.

Restraints in the Global Circulating Tumor Cell Market

The primary barrier to widespread acceptance in the industry is the intricacy of technology, and the need for consistency in CTC analysis methods creates difficult circumstances. Furthermore, problems pertaining to the consistency and repeatability of CTC effects hinder its integration into standard medical practice.

Market Trends of the Global Circulating Tumor Cell Market

There has been a noticeable change in favor of incorporating CTC examination into routine medical procedures, driven by its ability to track the course of disease and the response to treatment in real time. The continuous advancement of cutting-edge technology, such as improved molecular detection techniques and microfluidic devices, shows a trend toward increased sensitivity and precision in CTC analysis. Furthermore, the increasing awareness of liquid biopsy techniques in cancer diagnosis highlights the importance of CTCs as useful biomarkers.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Pricing Analysis
• Start Up Analysis
• Regulatory Landscape
• Patent Analysis
• Pipeline Analysis
• Key Success Factors
• Market Attractiveness Index
• Degree of Competition
• Top Investment Pockets
• Ecosystem Mapping

Circulating Tumor Cell Market by Technology

• Market Overview
• CTC Detection
  • Immunocapture
  • Size-based separation
  • Density-Based Separation
  • Combined Methods)
• CTC Detection method
  • SERS
  • Microscopy
  • Others
• CTC Analysis

Circulating Tumor Cell Market by Application

• Market Overview
• Clinical Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell
  • Drug Therapy Development

Circulating Tumor Cell Market by End User

• Market Overview
• Hospitals & Clinics,
• Research & Academic Institutes
• Diagnostic Centres

Circulating Tumor Cell Market by Product

• Market Overview
• Kits & Reagents
• Blood Collection Tubes
• Devices or Systems

Circulating Tumor Cell Market by Specimen

• Market Overview
• Blood
• Bone Marrow
• Other body fluid

Circulating Tumor Cell Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Janssen Diagnostics (Johnson & Johnson)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex America, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BD (Becton, Dickinson and Company)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macrogenics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personalis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ANGLE PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ApoCell, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RareCyte, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exosomedx
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grail, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invivoscribe Technologies, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epic Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Circulating Biomarkers LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ClariCell, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thrive Earlier Detection
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ellumen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hera BioLabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CellMax Life Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments